Atlas Trials

A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment

Clinical trial NCT05133531 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05133531
Sponsor
Regeneron Pharmaceuticals
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Paroxysmal Nocturnal Hemoglobinuria
Start date
2022-08-01
Primary completion
2026-10-12
Enrollment
202

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.